Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement.
This clinical study was undertaken to evaluate the use of tissue-engineered bone, mesenchymal stem cells, platelet-rich plasma, and beta-tricalcium phosphate as grafting materials for maxillary sinus floor augmentation or onlay plasty with simultaneous implant placement in six patients with 3- to 5-mm alveolar crestal bone height. All 20 implants were clinically stable at second-stage surgery and 12 months postloading. A mean increase in mineralized tissue height of 7.3+/-4.6 mm was evident when comparing the pre- and postsurgical radiographs. Injectable tissue-engineered bone provided stable and predictable results in terms of implant success.
Ueda
Minoru
M
Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine, Showa-Ku, Nagoya 466-8550, Japan. mueda@med.nagoya-u.ac.jp
Yamada
Yoichi
Y
Ozawa
Ryotaro
R
Okazaki
Yasuhiro
Y
D020341:Absorbable Implants; D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000601:surgery; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D001792:Blood Platelets; D001861:Bone Regeneration; D016025:Bone Transplantation / Q000379:methods*; D002130:Calcium Phosphates; D003758:Dental Implantation, Endosseous / Q000379:methods*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008443:Maxillary Sinus / Q000601:surgery*; D045164:Mesenchymal Stem Cell Transplantation; D008875:Middle Aged; D013516:Oral Surgical Procedures, Preprosthetic; D010956:Plasmapheresis; D023822:Tissue Engineering
D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate